search
Back to results

Targeted Screening of At-Risk Adults for Acute HIV-1 Infection (AHI)

Primary Purpose

HIV

Status
Completed
Phase
Not Applicable
Locations
Kenya
Study Type
Interventional
Intervention
intense follow up
Sponsored by
University of Oxford
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV focused on measuring HIV-1, acute, diagnosis, pharmacies, healthcare facilities

Eligibility Criteria

18 Years - 29 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • symptom score of 2 or more: Confirmed fever (≥37.5 °C axillary), reported diarrhoea, or evidence of STD (variable score=2); reported body pains, or report of more than one sexual partners in past 2 months (variable score=1)
  • resident in Mtwapa or Shanzu or planning to stay in Mtwapa for approximately 4 weeks duration
  • willing to give locator information (including mobile phone number)
  • negative or unknown HIV status

Exclusion Criteria:

  • patients not meeting inclusion criteria

Sites / Locations

  • KEMRI Mtwapa

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intense follow up

standard follow-up

Arm Description

2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.

2-week follow-up appointment with no reminders

Outcomes

Primary Outcome Measures

Difference in Number and proportion of adults responding to standard appointment versus intense follow up.

Secondary Outcome Measures

Number and proportion of adults diagnosed with AHI by rapid antibody seroconversion.

Full Information

First Posted
June 10, 2013
Last Updated
August 1, 2014
Sponsor
University of Oxford
Collaborators
International AIDS Vaccine Initiative, KEMRI-Wellcome Trust Collaborative Research Program, University of Washington, Kenya Ministry of Health
search

1. Study Identification

Unique Protocol Identification Number
NCT01876199
Brief Title
Targeted Screening of At-Risk Adults for Acute HIV-1 Infection
Acronym
AHI
Official Title
Targeted Screening of At-Risk Adults for Acute HIV-1 Infection
Study Type
Interventional

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
February 2013 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
July 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oxford
Collaborators
International AIDS Vaccine Initiative, KEMRI-Wellcome Trust Collaborative Research Program, University of Washington, Kenya Ministry of Health

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In this research, the investigators want to see if early detection of HIV infection can be improved by testing young adults who seek urgent health care from pharmacies and healthcare facilities with symptoms similar to those people get with recent HIV infection. Specific objectives: What proportion of people presenting with these symptoms are HIV positive at the point of seeking urgent health care? What proportion of those who test negative or where the result is unclear (one rapid test positive and one negative) at first rapid HIV testing, will test positive two weeks later? What is the best way (SMS, phone call or home visit) to remind people to come for the second test after two weeks? Will young adults who seek urgent health care for fever, body pains, diarrhoea or an STD from pharmacies or health facilities find it acceptable to be invited for an HIV-1 test at the time of health care seeking? Hypotheses Targeted screening for AHI among patients seeking health care for symptoms compatible with AHI or sexually transmitted disease (STD) will identify AHI cases in more than 1% of those screened. Intense follow-up of patients evaluated for AHI will improve rates of repeat HIV-1 testing 2-4 weeks after initial health-care seeking, relative to standard practice (i.e., recommendation to return for testing on a given date).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV
Keywords
HIV-1, acute, diagnosis, pharmacies, healthcare facilities

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
522 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intense follow up
Arm Type
Experimental
Arm Description
2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.
Arm Title
standard follow-up
Arm Type
No Intervention
Arm Description
2-week follow-up appointment with no reminders
Intervention Type
Behavioral
Intervention Name(s)
intense follow up
Primary Outcome Measure Information:
Title
Difference in Number and proportion of adults responding to standard appointment versus intense follow up.
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Number and proportion of adults diagnosed with AHI by rapid antibody seroconversion.
Time Frame
2 weeks
Other Pre-specified Outcome Measures:
Title
Number and proportion of adults diagnosed with AHI by p24 antigen testing alone
Time Frame
2 weeks
Title
Proportion of patients diagnosed with AHI who successfully enroll in HIV-1 care
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
29 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: symptom score of 2 or more: Confirmed fever (≥37.5 °C axillary), reported diarrhoea, or evidence of STD (variable score=2); reported body pains, or report of more than one sexual partners in past 2 months (variable score=1) resident in Mtwapa or Shanzu or planning to stay in Mtwapa for approximately 4 weeks duration willing to give locator information (including mobile phone number) negative or unknown HIV status Exclusion Criteria: patients not meeting inclusion criteria
Facility Information:
Facility Name
KEMRI Mtwapa
City
Kilifi
ZIP/Postal Code
80108
Country
Kenya

12. IPD Sharing Statement

Citations:
PubMed Identifier
27077745
Citation
Mugo PM, Wahome EW, Gichuru EN, Mwashigadi GM, Thiong'o AN, Prins HA, Rinke de Wit TF, Graham SM, Sanders EJ. Effect of Text Message, Phone Call, and In-Person Appointment Reminders on Uptake of Repeat HIV Testing among Outpatients Screened for Acute HIV Infection in Kenya: A Randomized Controlled Trial. PLoS One. 2016 Apr 14;11(4):e0153612. doi: 10.1371/journal.pone.0153612. eCollection 2016.
Results Reference
derived
Links:
URL
http://www.kemri-wellcome.org
Description
KEMRI Wellcome Trust Research Programme
URL
https://sitefinder.tghn.org/sites/kemri-wellcome-trust-research-programme/
Description
KEMRI Wellcome on SiteFinder

Learn more about this trial

Targeted Screening of At-Risk Adults for Acute HIV-1 Infection

We'll reach out to this number within 24 hrs